Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Elzonris (tagraxofusp-erzs) for the Treatment of BPDCN

Drug Name

Elzonris™ (tagraxofusp-erzs)

Developer

Stemline Therapeutics

Therapy Class

Cytotoxin

Product Description

CD123-directed cytotoxin

Current Indication

Blastic plasmacytoid dendritic cell neoplasm

Market Sector

Oncology

Developmental Status

Approved in the US
Expand
Close
Close
Close

Go Top